Immune Monitoring Package
Clinical Trial Support
How to Order
Serametrix gains CLIA certification for MDSC-based blood test for predicting response to immunotherapy in cancer patients
28 September 2016
MDSC-based Blood Test for Predicting Response to Cancer Therapy Commercialized by Serametrix
19 November 2013
Penn State Hershey and Serametrix to seek companion diagnostic for immunotherapy in pediatric cancers
16 April 2012
OncoSec and Serametrix Collaborate to Identify Potential Biomarkers to Enhance Skin Cancer Immune Therapies
16 November 2011
Serametrix launches test for measuring serum antibodies to leading cancer antigen NY-ESO-1
15 April 2010
Serametrix partners with the Ludwig Institute for Cancer Research to develop and commercialize serum-based diagnostics
14 October 2009
Dan Chambers Joins Serametrix as Chief Intellectual Property Counsel.
09 August 2009
Serametrix announces launch of Seromic™ product line.
28 May 2009
us today to learn how Serametrix can improve your results.
©2017 Serametrix l US: +1-760-652-4060 l Europe: +44 (0)20
Go to top